Video

Next-generation imaging and node-positive prostate cancer

Author(s):

Urology Times staff

Jason Zhu, MD, a medical oncologist at Levine Cancer Institute, part of Atrium Health, discusses how next-generation imaging, such as PSMA-PET imaging, is critical to advancing personalized medicine in patients with lymph node–positive prostate cancer after prostatectomy.

Related Videos
Eric Li, MD, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Jitesh Dhingra, MD, FRCEM, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Jitesh Dhingra, MD, FRCEM, answers a question during a Zoom video interview
Related Content
Enrollment goal met in phase 3 SOLAR-RECUR trial
November 22nd 2024

Enrollment goal met in phase 3 SOLAR-RECUR trial

Hannah Clarke
The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer following treatment with curative intent.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA
November 12th 2024

Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA

Hannah Clarke
The phase 1/2a SECuRE trial is evaluating the safety and efficacy of 67Cu-SAR-bisPSMA in the treatment of patients with mCRPC.
Study to inform definitive trial of 99mTc-sestaMIBI SPECT/CT for T1 renal tumors
November 12th 2024

Study to inform definitive trial of 99mTc-sestaMIBI SPECT/CT for T1 renal tumors

Hannah Clarke
The sensitivity of 99mTc-sestaMIBI SPECT/CT was 97%, and the specificity was 53.8%.
CMS adjusts reimbursement for diagnostic radiopharmaceuticals
November 5th 2024

CMS adjusts reimbursement for diagnostic radiopharmaceuticals

Hannah Clarke
The revised policy will take effect on January 1, 2025.
PSMA PET/CT can reveal prostate cancer recurrences before biochemical criteria met
October 29th 2024

PSMA PET/CT can reveal prostate cancer recurrences before biochemical criteria met

Hannah Clarke
“The majority (76%) of patients not yet meeting the Phoenix criteria did have PSMA-avid lesions on PSMA-PET, suggesting [prostate cancer] recurrence," says Evelien J E van Altena.
© 2024 MJH Life Sciences

All rights reserved.